Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

PURPOSE: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy. CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading to more robust immune responses. Increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellingsen, Espen B., O'Day, Steven, Mezheyeuski, Artur, Gromadka, Agnieszka, Clancy, Trevor, Kristedja, Timothy S., Milhem, Mohammed, Zakharia, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425723/
https://www.ncbi.nlm.nih.gov/pubmed/37378632
http://dx.doi.org/10.1158/1078-0432.CCR-23-0416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425723/
https://www.ncbi.nlm.nih.gov/pubmed/37378632
http://dx.doi.org/10.1158/1078-0432.CCR-23-0416

Ejemplares similares